Ovarian Cancer

Introgen's INGN 241 activates tumor selective cell death pathways

Published in Cancer Gene Therapy Week, July 4th, 2005

Researchers at Introgen Therapeutics, Inc. (INGN) and The University of Texas M. D. Anderson Cancer Center have identified a novel anti-cancer activity of mda-7, the active component of INGN 241.

In preclinical studies, expression of mda-7 in ovarian cancer cells potently activates a cell death (apoptosis) pathway regulated by the Fas signaling system, resulting in significant increases in apoptosis and inhibition of cancer cell proliferation.

These effects were specific to cancer cells, and were not observed in normal ovarian tissue, supporting previous data showing a cancer-selective effect of INGN 241. The data are reported in the current issue of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Gene Therapy Week

Source: Cancer Gene Therapy Week (2005-07-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry